Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02496104
Other study ID # HABIPREMA - RB 14.059
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 9, 2015
Est. completion date July 2026

Study information

Verified date February 2023
Source University Hospital, Brest
Contact Jean-Michel ROUE, Doctor
Email jean-michel.roue@chu-brest.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Each year in France, 7 % of newborns are born preterm (before 37 weeks of gestational age (GA)). The investigators called very preterm infants those who were born before 33 weeks of GA. These very preterm infants have a higher risk of developing neurological complications like developmental disabilities or cerebral palsy. To date, early assessment of these infants is difficult and not reliable enough to detect those who are at risks of developing neurological issues. Now, the investigators need to identify earlier these infants to provide them interventions to improve their development (physical therapy for example). Consequently, the investigators are examining a study whose aim is to assess preterm infants habituation. Habituation is the newborn ability to become familiar with new environmental stimulations (noise, light…). This habituation allows the newborn to maintain his sleep even at onset of a noise or light. To study this phenomenon in infants born preterm near to corrected term (around 40 weeks of postnatal GA), will allow us to better understand neurological development of these infants. The investigators plan to compare habituation skills of preterm infants near to their theorical date of birth (40 weeks of GA) to a population of infants born at term. The investigators will also study the link between habituation abilities and sleep quality as well as neurodevelopmental outcome at the corrected age of two years old.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date July 2026
Est. primary completion date July 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 2 Days to 10 Weeks
Eligibility Inclusion Criteria: - Preterm infants: preterm infants born from 25 weeks to 32 weeks + 6 days of gestation near to 36 weeks of gestation (corrected postnatal age) - Term infants: term newborns with a gestational age between 39 and 41 weeks of gestation at day 3 with an Apgar = 1 at 1 minute of life - For both groups: normal neurological physical examination, written informed consent of the parents Exclusion Criteria: - no malformation or chromosomal abnormality, life threatening disease, administration of morphine or sedatives during the 24 hours before the study, context of maternal drug addiction, deafness, no psychoactive drug or anticonvulsivants during the last month of pregnancy for the term newborns, severe neurological disease

Study Design


Intervention

Behavioral:
Package n°1 of the APIB


Locations

Country Name City State
France CHRU de Brest Brest

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of the package n°1 of the APIB (Assessment of Premature Infant's Behaviour) At 40 weeks of postnatal gestational age for the preterm infants and at 3 days old for the term newborns
Secondary Salivary cortisol changes Before and 30 minutes after the package n°1 of the APIB achievement
Secondary Oxy and deoxyhemoglobin changes in NIRS (Near-infrared Spectroscopy) During APIB package n°1 fulfillment
Secondary Heart rate variations During APIB package n°1 fulfillment
Secondary Oxymetry variations During APIB package n°1 fulfillment
Secondary Brief Infant Sleep Questionnaire At 6 and 12 months old (corrected age for the preterm infants)
Secondary Ages and Stages Questionnaire At 24 months old (corrected age for the preterm infants)